What question did this study set out to answer?

To characterize a rare EGFR mutation that caused resistance to osimertinib in a lung cancer patient.

June 12, 2026Lung CancerOpen Access

Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report

View Full Paper

Ask AI

Bookmark

Authors

Case report reveals a rare EGFR mutation leading to resistance in lung cancer, suggesting new treatment strategies.

To characterize a rare EGFR mutation that caused resistance to osimertinib in a lung cancer patient.
Case description of a lung cancer patient with an EGFR exon 19 deletion treated with osimertinib.
Re-biopsy and sequencing identified a novel EGFR exon 20 mutation, p.(Cys797Ala).
Immunohistochemical analysis evaluated phospho-EGFR and molecular modelling predicted treatment resistance.
The patient developed an acquired p.(Cys797Ala) mutation after five years on osimertinib.
Immunohistochemical analysis showed increased phospho-EGFR positivity, indicating receptor activation.
The patient benefitted from a trial that combined osimertinib with a SOS1 inhibitor, targeting the EGFR pathway.

García-Peláez et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark